FLAM
First Light Asset Management Portfolio holdings
AUM
$771M
This Quarter Return
+44.48%
1 Year Return
+33.17%
3 Year Return
+208.13%
5 Year Return
+426.73%
10 Year Return
+3,318.8%
AUM
$1.35B
AUM Growth
+$1.35B
(+38%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
8.23%
Top 10 Holdings %
Top 10 Hldgs %
52.62%
Holding
81
New
21
Increased
33
Reduced
4
Closed
7
Top Buys
| 1 |
Arrowhead Research
ARWR
|
$31.8M |
| 2 |
Health Catalyst
HCAT
|
$31.4M |
| 3 |
Halozyme
HALO
|
$28.4M |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$26.6M |
| 5 |
Prothena Corp
PRTA
|
$24.7M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$134M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$9.41M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$9.22M |
| 4 |
KORU Medical Systems
KRMD
|
$8.34M |
| 5 |
CareDx
CDNA
|
$7.43M |
Sector Composition
| 1 | Healthcare | 86.3% |
| 2 | Communication Services | 3.46% |
| 3 | Energy | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
AbbVie
ABBV
$374B
| $641K | 0.05% |
5,981
| – | – |
|
52
UnitedHealth
UNH
$279B
| $541K | 0.04% |
1,543
+851
| +123% | +$298K |
|
53
Becton Dickinson
BDX
$54.3B
| $416K | 0.03% |
+1,662
| New | +$416K |
|
54
Elevance Health
ELV
$72.4B
| $399K | 0.03% |
1,244
+449
| +56% | +$144K |
|
55
Merck
MRK
$210B
| $347K | 0.03% |
4,247
| – | – |
|
56
Johnson & Johnson
JNJ
$429B
| $340K | 0.03% |
2,161
| – | – |
|
57
Novartis
NVS
$248B
| $334K | 0.02% |
3,535
| – | – |
|
58
Cigna
CI
$80.2B
| $325K | 0.02% |
+1,560
| New | +$325K |
|
59
Sanofi
SNY
$122B
| $323K | 0.02% |
6,650
| – | – |
|
60
Bio-Rad Laboratories Class A
BIO
$7.8B
| $319K | 0.02% |
548
| – | – |
|
61
Pfizer
PFE
$141B
| $312K | 0.02% |
8,469
| – | -$16.8K |
|
|
SYNH
62
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $304K | 0.02% |
+4,469
| New | +$304K |
|
63
Envista
NVST
$3.37B
| $303K | 0.02% |
+8,985
| New | +$303K |
|
64
Agilent Technologies
A
$35.5B
| $302K | 0.02% |
2,548
| – | – |
|
65
Gilead Sciences
GILD
$140B
| $301K | 0.02% |
+5,175
| New | +$301K |
|
|
NUVA
66
DELISTED
NuVasive, Inc.
NUVA
| $294K | 0.02% |
+5,228
| New | +$294K |
|
67
CVS Health
CVS
$93B
| $286K | 0.02% |
+4,182
| New | +$286K |
|
68
Baxter International
BAX
$12.1B
| $261K | 0.02% |
3,258
| – | – |
|
69
Amgen
AMGN
$153B
| $251K | 0.02% |
1,092
| – | – |
|
70
Hologic
HOLX
$14.7B
| $243K | 0.02% |
3,340
| – | – |
|
71
Perrigo
PRGO
$3.21B
| $236K | 0.02% |
+5,275
| New | +$236K |
|
72
ICU Medical
ICUI
$3.06B
| $223K | 0.02% |
+1,041
| New | +$223K |
|
|
HRC
73
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $208K | 0.02% |
+2,121
| New | +$208K |
|
74
Grifois
GRFS
$6.53B
| $187K | 0.01% |
10,166
| – | – |
|
|
HGEN
75
DELISTED
HUMANIGEN, INC.
HGEN
| – | – |
-400,000
| Closed | -$4.26M |
|